Robustness assessment of clinical adaptive proton and photon radiotherapy for oesophageal cancer in the model-based approach

Lade...
Vorschaubild
Autor:innen
Visser, Sabine
O. Ribeiro, Cássia
Dieters, Margriet
Mul, Veronique E.
Niezink, Anne G.H.
van der Schaaf, Arjen
Langendijk, Johannes A.
Korevaar, Erik W.
Both, Stefan
Muijs, Christina T.
Autor:in (Körperschaft)
Publikationsdatum
12/2022
Typ der Arbeit
Studiengang
Typ
01A - Beitrag in wissenschaftlicher Zeitschrift
Herausgeber:innen
Herausgeber:in (Körperschaft)
Betreuer:in
Übergeordnetes Werk
Radiotherapy and Oncology
Themenheft
Link
Reihe / Serie
Reihennummer
Jahrgang / Band
177
Ausgabe / Nummer
Seiten / Dauer
197-204
Patentnummer
Verlag / Herausgebende Institution
Elsevier
Verlagsort / Veranstaltungsort
Auflage
Version
Programmiersprache
Abtretungsempfänger:in
Praxispartner:in/Auftraggeber:in
Zusammenfassung
Purpose In the Netherlands, oesophageal cancer (EC) patients are selected for intensity modulated proton therapy (IMPT) using the expected normal tissue complication probability reduction (ΔNTCP) when treating with IMPT compared to volumetric modulated arc therapy (VMAT). In this study, we evaluate the robustness of the first EC patients treated with IMPT in our clinic in terms of target and organs-at-risk (OAR) dose with corresponding NTCP, as compared to VMAT. Materials and Methods For 20 consecutive EC patients, clinical IMPT and VMAT plans were created on the average planning 4DCT. Both plans were robustly evaluated on weekly repeated 4DCTs and if target coverage degraded, replanning was performed. Target coverage was evaluated for complete treatment trajectories with and without replanning. The planned and accumulated mean lung dose (MLD) and mean heart dose (MHD) were additionally evaluated and translated into NTCP. Results Replanning in the clinic was performed more often for IMPT (15x) than would have been needed for VMAT (8x) (p = 0.11). Both adaptive treatments would have resulted in adequate accumulated target dose coverage. Replanning in the first week of treatment had most clinical impact, as anatomical changes resulting in insufficient accumulated target coverage were already observed at this stage. No differences were found in MLD between the planned dose and the accumulated dose. Accumulated MHD differed from the planned dose (p < 0.001), but since these differences were similar for VMAT and IMPT (1.0 and 1.5 Gy, respectively), the ΔNTCP remained unchanged. Conclusion Following an adaptive clinical workflow, adequate target dose coverage and stable OAR doses with corresponding NTCPs was assured for both IMPT and VMAT.
Schlagwörter
IMPT, VMAT, Robustness, Oesophageal cancer, Dose accumulation, Model-based approach
Fachgebiet (DDC)
600 - Technik, Medizin, angewandte Wissenschaften
Projekt
Veranstaltung
Startdatum der Ausstellung
Enddatum der Ausstellung
Startdatum der Konferenz
Enddatum der Konferenz
Datum der letzten Prüfung
ISBN
ISSN
0167-8140
Sprache
Englisch
Während FHNW Zugehörigkeit erstellt
Nein
Zukunftsfelder FHNW
Publikationsstatus
Veröffentlicht
Begutachtung
Peer-Review der ganzen Publikation
Open Access-Status
Hybrid
Lizenz
'https://creativecommons.org/licenses/by-nc-nd/4.0/'
Zitation
VISSER, Sabine, Cássia O. RIBEIRO, Margriet DIETERS, Veronique E. MUL, Anne G.H. NIEZINK, Arjen VAN DER SCHAAF, Johannes A. LANGENDIJK, Erik W. KOREVAAR, Stefan BOTH, Christina T. MUIJS und Antje KNOPF, 2022. Robustness assessment of clinical adaptive proton and photon radiotherapy for oesophageal cancer in the model-based approach. Radiotherapy and Oncology. Dezember 2022. Bd. 177, S. 197–204. DOI 10.1016/j.radonc.2022.11.001. Verfügbar unter: https://doi.org/10.26041/fhnw-4840